(Abst.) Siponimod following alemtuzumab for SPMS... on: August 18, 2024, 11:36:27 am #1 From PubMed (August 18, 2024)--"Siponimod following alemtuzumab for secondary progressive multiple sclerosis: Investigating sequential therapy--a case series": Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy-A case series - PubMed Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is approved for treatment of highly active relapsing multiple sclerosis (MS) but requires vigilant post-treatment monitoring due to associate... PubMed · pubmed.ncbi.nlm.nih.gov QuoteThe prescription of subsequent therapies following Alemtuzumab, as mandated by label guidance for a treatment-free period of at least 5 years, presents a complex challenge, particularly if there is concurrent conversion to secondary progressive disease course. That 5-year wait before starting another MS treatment after stopping alemtuzumab would probably be a drawback for many patients. Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
